A protein in tumor tissue may show which meningiomas come back
Original title: The superior prognostic role of pRB1 over p16 immunohistochemistry as a biomarker in meningiomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at stored tumor samples from patients, not a test of a treatment.
The short version
A protein called pRB1 in tumor tissue may signal a higher chance that a meningioma grows back.
What was studied. Researchers looked back at 1751 stored meningioma tumor samples from one center. They stained the samples for four proteins: p16, pRB1, CDK4 and CDK6.
What they found. p16 showed up in 14.9% (n = 261) of the samples. High pRB1 levels were found in 34.5% (n = 589). CDK4 was positive in 41.9% of cases, and CDK6 in 42.2%. High pRB1 was linked to a shorter time before the tumor came back, even after other things were taken into account. The link seen with p16 seemed to come from pRB1 instead.
What this means, and what it doesn't
What it could mean: Checking tumor tissue for pRB1 might help doctors spot who needs closer follow up. It may be a more useful marker than p16.
What it doesn't mean: This is not a treatment, and it is not a cure. It was a look back at old tumor samples from one hospital. This kind of study can show a link, but it cannot prove cause. The test is not part of standard care today. No one has shown it helps people live longer or better. More study is needed first.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.